Education
Education
Applications
Therapies
As of September 2016
Click on the "+" icons below to view tables with information on selected personalized therapies and their indications.
- ADJUVANT THERAPY
| Drug Name (Brand Name) | Biomarker(s) | Indication |
| Cevimeline (Evoxac ®) | CYP2D6 | Dry mouth |
| Rasburicase (Elitek ®) | G6PD; CYB5R1-4 | Hyperuricemia, hemolysis, and methemoglobinemia |
| Sodium phenylacetate & sodium benzoate (Ammonul ®) | NAGS; CPS1; ASS1; OTC; ASL; ARG | Urea cycle disorders |
| Sodium phenylbutyrate (Buphenyl ®) | CPS1; OTC; ASS1 | Urea cycle disorders |
- ANALGESIA & ANESTHESIOLOGY
| Drug Name (Brand Name) | Biomarker(s) | Indication |
| Celecoxib (Celebrex ®) | CYP2C9 | Pain |
| Codeine | CYP2D6; CYP3A4; UGT2B7 | Pain |
| Mivacurium (Mivacron ®) | Cholinesterase gene | Anesthesia adjunct |
| Tramadol (Ultram ®) | CYP2D6 | Pain |
- CARDIOVASCULAR (CV)
| Drug Name (Brand Name) | Biomarker(s) | Indication |
| Carvedilol (Coreg ®) | CYP2D6 | Cardiovascular disease |
| Clopidogrel (Plavix ®) | CYP2C19 | Antiplatelet response |
| Isosorbide and hydralazine (Bidil ®) | NAT1; NAT2 | Heart failure |
| Lomitapide | LDLR | Familial hypercholesterolemia |
| Metoprolol (Toprol-XL ®) | CYP2D6 | Cardiovascular disease |
| Mipomersen sodium (Kynamro ®) | LDLR | Familial hypercholesterolemia |
| Pravastatin | LDR | High cholesterol |
| Propafenone (Rythmol SR ®) | CYP2D6 | Cardiac arrhythmia |
| Quinidine | CYP2D6 | Cardiac arrhythmia, malaria |
| Simvastatin (Zocor ®) | SLCO1B1 | High cholesterol |
| Warfarin (Coumadin ®) | CYP2C9; VKORC1; protein C or S deficiencies | Anti-blood clotting, stroke prevention |
- ENDOCRINOLOGY
| Drug Name (Brand Name) | Biomarker(s) | Indication |
| Glyburide | G6PD | Diabetes |
| Chlorpropamide | G6PD | Diabetes |
| Glimepiride | G6PD; CYP2C9 | Diabetes |
| Glipizide | G6PD | Diabetes |
- GASTROENTEROLOGY
| Drug Name (Brand Name) | Biomarker(s) | Indication |
| Dexlansoprazole (Dexilant ®) | CYP2C19 | Heartburn, gastroesophageal reflux disease, and esophageal damage |
| Esomeprazole (Nexium ®) | CYP2C19 | Acid indigestion, peptic ulcer disease, and gastroesophageal reflux disease |
| Lansoprazole (Prevacid ®) | CYP2C19 | Peptic ulcer disease, gastroesophageal reflux disease |
| PEG-3350, sodium sulfate, sodium chloride, potassium chloride, sodium ascorbate, and ascorbic acid (Moviprep ®) | G6PD | Laxative |
| Rabeprazole (Aciphex ®) | CYP2C19 | Gastroesophageal reflux disease |
- HEMATOLOGY
| Drug Name (Brand Name) | Biomarker(s) | Indication |
| Eltrombopag (Promacta ®) | F5; SERPINC1 | Thrombocytopenia, aplastic anemia |
| Methylene blue (Provayblue™) | G6PD | Methemoglobinemia |
- IMMUNOLOGY
| Drug Name (Brand Name) | Biomarker(s) | Indication |
| Indacaterol (Arcapta ®) | UGT1A1 | COPD |
- INFECTIOUS DISEASE
| Drug Name (Brand Name) | Biomarker(s) | Indication |
| Abacavir (Ziagen ®) | HLA-B*57:01 | HIV |
| Atazanavir (Reyataz ®) | UGT1A1 | HIV |
| Boceprevir (Victrelis ®) | IFNL3 | Hepatitis C |
| Chloroquine (Aralen ®) | G6PD | Malaria |
| Dapsone | G6PD | Leprosy |
| Isoniazid (Nydrazid ®) | NAT1; NAT2 | Tuberculosis |
| Mafenide (Sulfamylon ®) | G6PD | Burns |
| Maraviroc (Selzentry ®) | CCR5 receptor | HIV |
| Nitrofurantoin (Furadantin ®) | G6PD | Urinary tract infections |
| Peginterferon alfa-2b (Pegasys ®) | IL28B | Hepatitis B, hepatitis C |
| Primaquine | G6PD | Malaria |
| Pyrazinamide (Rifater ®) | NAT1; NAT2 | Tuberculosis |
| Quinine sulfate | G6PD; CYP2D6; CYP3A4 | Malaria |
| Rifampin (Rifadin ®) | NAT1; NAT2 | Tuberculosis |
| Sulfamethox-azole and trimethoprim (Bactrim ®) | G6PD | Bacterial infections |
| Telaprevir (Incivek ®) | IFNL3 | Hepatitis C |
| Voriconazole (Vfend ®) | CYP2C19 | Fungal infections |
- METABOLIC
| Drug Name (Brand Name) | Biomarker(s) | Indication |
| Allopurinol | HLA-B*58:01 | High blood uric acid levels, gout |
- NEUROLOGY
| Drug Name (Brand Name) | Biomarker(s) | Indication |
| Carbamazepine (Tegretol ®) | HLA-B*15:02; HLA-A*31:01 | Epilepsy, bipolar disorder |
| Carisoprodol (Soma ®) | CYP2C19 | Musculoskeletal pain |
| Clobazam (Onfi ®) | CYP2C19 | Lennox-Gastaut syndrome |
| Dextrometorphan & Quinidine (Nuedexta ®) | CYP2D6 | Pseudobulbar affect |
| Divalproex (Depakote ®) | UCD (NAGS; CPS; ASS; OTC; ASL; ARG) | Bipolar disorder (antiepileptic drug) |
| Phenytoin (Dilantin ®) | HLA-B; CYP2C9 | Prevention of seizures |
| Tetrabenazine (Xenazine ®) | CYP2D6 | Huntington's disease |
| Valproic acid (Depakene ®) | OTC; POLG; NAGS; CPS1; ASS1; ASL; ABL2 | Epilepsy |
| Vortioxetine (Trintellix™) | CYP2D6 | Depression |
- ONCOLOGY
| Drug Name (Brand Name) | Biomarker(s) | Indication |
| ado-trastuzumab emtansine (Kadcyla ®) | ERBB2 | Breast cancer |
| Afatinib (Gilotrif ®) | EGFR | Metastatic non-small cell lung cancer |
| Anastrozole (Arimidex ®) | ESR1; PGR | Breast cancer |
| Arsenic trioxide (Trisenox ®) | PML-RARA | Acute promyelocytic leukemia |
| Busulfan (Busulfex ® & Myleran ®) | BCR-ABL1 | Leukemia |
| Bosutinib (Bosulif ®) | BCR-ABL1 | Leukemia |
| Brentuximab Vedotin (Adcetris™) | CD30 | Hodgkin's lymphoma, anaplastic large cell lymphoma |
| Capecitabine (Xeloda ®) | DPYD | Multiple cancers |
| Cetuximab (Erbitux ®) | EGFR, KRAS | Colon cancer |
| Crizotinib (Xalkori ®) | ALK | Lung cancer |
| Dabrafenib (Tafinlar ®) | BRAF; G6PD | Melanoma |
| Dasatinib (Sprycel ®) | BCR-ABL | Leukemia |
| Denileukin diftitox (Ontak ®) | IL2RA | Lymphoma |
| Erlotinib (Tarceva ®) | EGFR | Non-small cell lung cancer |
| Everolimus (Afinitor ®) | ERBB2; ESR1 | Breast cancer |
| Exemestane (Aromasin ®) | ESR1; PGR | Breast cancer |
| 5-Fluorouracil (5-FU) (Efudex ®) | DPYD | Multiple cancers |
| Fulvestrant (Faslodex ®) | ESR1; PGR | Breast cancer |
| Gefitinib (Iressa ®) | EGFR | Non-small cell lung cancer |
| Imatinib (Gleevec ®) | BCR-ABL; PDGFRB; KIT; FIP1L1-PDGFRA | Multiple cancers, myelodysplastic syndrome |
| Irinotecan (Camptosar ®) | UGT1A1 | Colon cancer, small cell lung cancer |
| Lapatinib (Tykerb ®) | ERBB2; HLA-DQA1; HLA-DRB1 | Breast cancer |
| Lenalidomide (Revlimid ®) | Del (5q) | Multiple myeloma, mantle cell lymphoma, and myelodysplastic syndrome |
| Letrozole (Femara ®) | ESR1; PGR | Breast cancer |
| Mercaptopurine (Purinethol ®) | TPMT | Acute lymphocytic leukemia, chronic myeloid leukemia, Crohn's disease, ulcerative colitis |
| Nilotinib (Tasigna ®) | UGT1A1; BCR-ABL1 | Chronic myelogenous leukemia |
| Obinutuzumab (Gazyva ®) | MS4A1 | Chronic lymphocytic leukemia, follicular lymphoma |
| Omacetaxine mepesuccinate (Synribo ®) | BCR-ABL1 | Chronic myeloid leukemia |
| Panitumumab (Vectibix ®) | EGFR; KRAS | Colon cancer |
| Pemetrexed (Alimta ®) | TS | Lung cancer |
| Pertuzumab (Perjeta ®) | ERBB2 | Breast cancer |
| Platinum Therapies | ||
| Carboplatin | ERCC1 | Ovarian cancer |
| Cisplatin | TPMT | Multiple cancers |
| Oxaliplatin | ERCC1 | Colorectal cancer |
| Nedaplatin | ERCC1 | Multiple cancers |
| Triplatin tetranitrate | ERCC1 | Multiple cancers |
| Satraplatin | ERCC1 | Multiple cancers |
| Ponatinib (Iclusig ®) | BCR-ABL1 | Chronic lymphocytic leukemia, acute lymphocytic leukemia |
| Rituximab (Rituxan ®) | MS4A1 | Non-Hodgkin's lymphoma, chronic lymphocytic leukemia, and autoimmune diseases |
| Tamoxifen (Nolvadex ®) | ESR1; ESR2; PGR; F5; F2; CYP2D6 | Breast cancer |
| Thioguanine (Tabloid ®) | TPMT | Acute myeloid leukemia, acute lymphocytic leukemia, and chronic myeloid leukemia |
| Tositumomab (Bexxar ®) | MS4A1 | Non-Hodgkin's lymphoma |
| Trametinib (Mekinist ®) | BRAF | Melanoma |
| Trastuzumab (Herceptin ®) | ERBB2 | Breast cancer |
| Tretinoin (Vesanoid ®) | PML/RARalpha | Acute promyelocytic leukemia |
| Vemurafenib (Zelboraf™) | BRAF; NRAS | Melanoma |
- PSYCHIATRY
| Drug Name (Brand Name) | Biomarker(s) | Indication |
| Aripiprazole (Abilify ®) | CYP2D6 | Schizophrenia, bipolar disorder |
| Amitriptyline (Elavil ®) | CYP2C19 | Depression |
| Atomoxetine (Strattera ®) | CYP2D6 | ADHD |
| Citalopram (Celexa ®) | CYP2C19 | Depression |
| Clomipramine (Anafranil ®) | CYP2D6 | Depression |
| Clozapine (Clozaril ®) | CYP2D6 | Schizophrenia |
| Desipramine (Norpramin ®) | CYP2D6 | Depression |
| Doxepin (Silenor ®) | CYP2C19 | Insomnia, depression |
| Fluoxetine (Prozac ®) | CYP2D6 | Depression |
| Fluvoxamine (Luvox CR ®) | CYP2D6 | Obsessive compulsive disorders |
| Iloperidone (Fanapt ®) | CYP2D6 | Schizophrenia |
| Imipramine (Tofranil-PM ®) | CYP2C19 | Depression |
| Nortriptyline (Pamelor ®) | CYP2D6 | Depression |
| Paroxetine (Pexeva ®) | CYP2D6 | Major depressive disorder, obsessive compulsive disorder, panic disorder, and generalized anxiety disorder |
| Perphenazine (Trilafon ®) | CYP2D6 | Schizophrenia |
| Pimozide (Orap ®) | CYP2D6 | Tourette's syndrome |
| Protriptyline (Vivactil ®) | CYP2D6 | Depression |
| Risperidone | CYP2D6 | Schizophrenia, bipolar mania, irritability with autistic disorder |
| Thioridazine (Mellaril ®) | CYP2D6 | Schizophrenia |
| Trimipramine (Surmontil ®) | CYP2C19 | Depression |
- PULMONARY
| Drug Name (Brand Name) | Biomarker(s) | Indication |
| Ivacaftor (Kalydeco ®) | CFTR | Cystic fibrosis |
- RHEUMATOLOGY
| Drug Name (Brand Name) | Biomarker(s) | Indication |
| Azathioprine (Imuran ®) | TPMT | Rheumatoid arthritis, organ transplant |
| Flurbiprofen (Ansaid ®) | CYP2C9 | Arthritis |
| Pegloticase (Krystexxa ®) | G6PD | Uric acid management, gout |
- TOXICOLOGY
| Drug Name (Brand Name) | Biomarker(s) | Indication |
| Sodium nitrate | G6PD | Cyanide poisoning |
- TRANSPLANTATION
| Drug Name (Brand Name) | Biomarker(s) | Indication |
| Mycophenolic acid (Myfortic ®) | HPRT1 | Kidney transplant |
| Tacrolimus | CYP3A5 | Organ transplant |
- UROLOGY
| Drug Name (Brand Name) | Biomarker(s) | Indication |
| Tolterodine (Detrol ®) | CYP2D6 | Overactive bladder |
If you have suggestions or updates for this page please contact Daryl Pritchard at dpritchard@personalizedmedicinecoalition.org.